

ASX Announcement

Clinical Milestones Webinar

Sydney Australia, 28 February 2025: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), (**Recce or the Company**), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce a live online webinar to provide insights into the Company's latest Phase II clinical trial dataset, new pre-clinical data, and its ongoing operational activities including a Registrational Phase 3 Clinical Trial in Indonesia.

The event will feature segments from experts in their respective fields and highlight the Company's significant progress across its portfolio of anti-infective programs. It will feature speakers from Recce Pharmaceuticals, Barwon Health and the Company's Anti-Infective Research Unit at Murdoch Children's Research Institute.

The event will be held online via Zoom on **3rd of March 2025 at 11AM AEDT**.

A copy of the presentation slides will be made available via the ASX prior to the online presentation and a full recording made available via Recce Pharmaceuticals' website following the event. Please register using the link below:

https://us02web.zoom.us/webinar/register/WN_iL-KjIMxQ--LEKWvRiQn5Q

This announcement has been approved for release by Recce Pharmaceuticals Board.



ASX: RCE, **FSE:** R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 **T** +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA